Drugs / rDEN1Δ30
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02392325 | Mar 2015 → Jul 2016 | dengue disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rDEN1Δ30 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02392325 ↗ |
| Route | Subcutaneous | “Administered subcutaneously in 0.5 mL containing 10\^3.0 plaque-forming units (PFU)” NCT02392325 ↗ |